Treatment of HBV-related cirrhosis

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 5, 2009, Pages 527-535

  Vallet Pichard, Anais ^b   Mallet, Vincent ^b   Costentin, Charlotte E ^a   Pol, Stanislas ^a,b  

^a Hôpital Cochin ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cirrhosis; HBV; Hepatitis B virus; Hepatocellular carcinoma; Nucleoside and nucleotide analogues

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; NUCLEOTIDE; RECOMBINANT INTERFERON;

ANTIVIRAL RESISTANCE; COMBINATION CHEMOTHERAPY; DEATH; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PORTAL HYPERTENSION; REVIEW; RISK REDUCTION; VACCINATION; VIRUS INHIBITION; VIRUS REPLICATION; BLOOD; DRUG EFFECT; FEMALE; ISOLATION AND PURIFICATION; MALE; VIROLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; LIVER CIRRHOSIS; MALE; NUCLEOTIDES;

EID: 68249162589     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.28     Document Type: Review

References (46)

1. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45, 1056-1075 (2007). (Pubitemid 46646501)
2. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin. Liver Dis. 25, 40-47 (2005).
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 45, 507-539 (2007).
4. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin. Liver Dis. 26, 142-152 (2006).
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasison disease progression and prognostic factors. J. Hepatol. 48, 335-352 (2008).
6. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long term outcome of chronic B hepatitis in Caucasian patients: mortality after 25 years. Gut 57, 84-90 (2008).
7. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma: incidence and risk factors. Gastroenterology 127, S35-S50 (2004). (Pubitemid 39423368)
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009). •• A panel of hepatologist experts gives the last recommendations regarding the treatment of HBV infection.
9. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531 (2004).
10. Manno M, Camma C, Schepis F et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 127, 756-763 (2004). (Pubitemid 39208409)
11. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29 year longitudinal study. Hepatology 43, 556-562 (2006).
12. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686 (2006). (Pubitemid 43374518)
13. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006). (Pubitemid 43042691)
14. Huo Ti, Wu JC, Hwang SJ et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study. Eur. J. Gastroenterol. Hepatol. 12, 687-693 (2000).
15. Park BK, Park YN, Ahn SH et al. Long term outcome of chronic hepatitis B based on histological grade and stage. J. Gastroenterol. Hepatol. 22, 383-388 (2007).
16. Hsu YS, Chien RN, Yeh CT et al. Long term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35, 1522-1527 (2002).
17. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med. 116, 829-834 (2004). (Pubitemid 38721324)
18. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 123, 1848-1856 (2002).
19. Toan NL, Song LH, Kremsner PG et al. Impact of the hepatitis B virus genotype and genotypes mixtures on the course of the liver disease in Vietnam. Hepatology 43, 1375-1384 (2006).
20. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 130, 1153-1168 (2006).
21. Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J. Infect. Dis. 193, 1258-1265 (2006).
22. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126, 1024-1029 (2004).
23. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J. Hepatol. 44, S65-S70 (2006). (Pubitemid 43053877)
24. Puoti M, Cozzi-Lepri A, Arici C et al. Impact of lamivudine on the risk of liver-related death in 2041 HBsAg- and HIV-positive individuals: results from an inter cohort analysis. Antivir. Ther. 11, 567-574 (2006). (Pubitemid 44277421)
25. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environnemental factors: a systematic review of the epidemiologic evidence. Oncogene 25, 3756-3770 (2006). (Pubitemid 43980471)
26. Bondini S, Kallman J, Wheeler A et al. Impact on non alcoholic fatty liver disease on chronic B hepatitis. Liver Int. 27, 607-611 (2007). (Pubitemid 47097309)
27. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases risk of hepatocellular carcinoma in the United-States: a population based case control study. Gut 54, 533-539 (2005). (Pubitemid 40403031)
28. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25, 3823-3833 (2006). (Pubitemid 43980478)
29. Hache C, Villeneuve J-P. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin. Pharmacother. 7, 1835-1843 (2006).
30. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of α-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann. Intern. Med. 119, 312-323 (1993). (Pubitemid 23319890)
31. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon α-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005). (Pubitemid 41007823)
32. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365, 123-129 (2005). (Pubitemid 40091801)
33. Marcellin P, Lau GKK, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004). (Pubitemid 39296307)
34. Niederau K, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon α for chronic hepatitis B. N. Engl. J. Med. 334, 1422-1427 (1996). (Pubitemid 26157437)
35. Buster EH, Hansen BE, Buti M et al. Peginterferon α-2b is safe and effective in AgHBe-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46, 388-394 (2007). • Shows that pegylated interferon is effective and safe in patients with advanced fibrosis, including cirrhosis. (Pubitemid 47344773)
36. Lai CL, Gane E, Liaw YF et al.; Globe study group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007). (Pubitemid 350294224)
37. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808-816 (2003). (Pubitemid 36245756)
38. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006). •• One of the pivotal studies comparing entecavir and lamivudine, and clearly showing the superiority of entecavir for HBV suppression, but also concerning the resistance profile.
39. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442-2455 (2008). •• Pivotal study comparing tenofovir and adefovir, and showing the superiority of tenofovir for HBV suppression.
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
41. Lai CL, Shouval D, Lok A et al. Entecavir versus lamivudine for patients with HBe Ag-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006). •• One of the pivotal studies comparing entecavir and lamivudine, and clearly showing the superiority of entecavir for HBV suppression, but also concerning the resistance profile. (Pubitemid 43357804)
42. Serpaggi J, Carnot F, Nalpas B et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum. Pathol. 37, 1519-1526 (2006). (Pubitemid 44792230)
43. Farci P, Roskams T, Chessa L et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126, 1740-1749 (2004). (Pubitemid 38736339)
44. Mallet VO, Dhalluin-Venier V, Verkarre V et al. Reversibility of cirrhosis in HIV/HBV co-infection. Antivir. Ther. 12, 279-283 (2007).
45. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 45, 804-817 (2005).
46. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133, 1445-1451 (2007). (Pubitemid 350047463)